DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this compound. Additional details are available on the fedratinib hydrochloride profile page.
Generic Entry Opportunity Date for 212327
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||CAPSULE;ORAL||Strength||EQ 100MG BASE|
|Approval Date:||Aug 16, 2019||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Aug 16, 2024|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||Start Trial||Patent Expiration:||May 29, 2032||Product Flag?||Y||Substance Flag?||Delist Request?|
|Patented Use:||TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS|
|Patent:||Start Trial||Patent Expiration:||Dec 16, 2026||Product Flag?||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription